Lupin Latest News
-
Lupin has informed that the company will be participating in the J P Morgan Global Healthcare Conference to be held on Tuesday, January 12, 2021.Date:11-01-2021
-
Lupin has received tentative approval for its Empagliflozin and Metformin Hydrochloride ER TabletsDate:08-01-2021
-
Lupin has informed that it has enclosed a Press Release on 7th January 2021, as regards receipt of tentative USFDA approval for the Company's Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, 5 mg/10...
Date:07-01-2021 -
The product will be manufactured at Lupin's Nagpur facility in IndiaDate:07-01-2021
-
BCPL Railway Infrastructure has received a LoA from Howrah Division – Electrical, Eastern RailwayDate:07-01-2021
-
Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, is indicated for the treatment and prevention of a wide variety of bacterial infectionsDate:06-01-2021
-
Mycophenolate Mofetil Tablets USP, 500 mg, are the generic equivalent of CellCept Tablets of Roche Palo Alto LLCDate:29-12-2020
-
Meloxicam Capsules (RLD: Vivlodex) had an annual sales of approximately $ 11 million in the U.S. (IQVIA MAT October 2020)Date:28-12-2020
-
Lupin has informed that it has enclosed a Press Release on 28th December 2020 as regards the launch by the Company of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the US FDA, titled ‘Lupin launche...
Date:28-12-2020 -
Meloxicam Capsules (RLD: Vivlodex) had an annual sales of approximately $ 11 million in the U.S. (IQVIA MAT October 2020)Date:28-12-2020
SEBI Registered: Investment Adviser - 
+91 20 6725 8333